Natera, Inc., a global leader in cell-free DNA and precision medicine, announced a significant expansion of its operations, marking a major milestone in the company’s continued growth and mission to improve outcomes for patients with cancer and other serious diseases.
At its North Austin headquarters campus, Natera will unveil two major expansion projects: a dedicated sequencing facility, significantly increasing capacity; and an additional space in a second building within the same complex, designed to support continued business growth and operational scale.
Natera’s facility is expected to have the largest sequencing capacity in the world. This new space will help enable the company to meet the increasing demand for its testing solutions, particularly in oncology where year-over-year volumes increased by more than 54% in the first quarter of 2026. Natera's SignateraTM test has become a foundational tool in precision oncology and is used today by more than 50% of U.S. oncologists. Last week, SignateraTM CDx became the first FDA-approved companion diagnostic in molecular residual disease testing.
Natera is also continuing to support substantial investments in research and development, with participation in hundreds of clinical trials and research collaborations across its business. These efforts are helping generate the evidence needed to expand the use of personalized diagnostics and bring new innovations to patients worldwide.
“With this expansion, we will have an even greater opportunity to serve patients,” said John Fesko, president, chief business officer of Natera. “By expanding our lab space and sequencing capacity, we are investing in the infrastructure needed to serve more patients, support additional clinicians, and continue advancing personalized medicine at scale.”
Natera expects to create up to 400 new jobs across professional, laboratory, and operational roles through this expansion.